Imugene Limited featured photo
Visual supplier profile

Imugene Limited

Clinical stage immuno oncology company in Sydney, Australia developing CAR T cell therapy, B cell vaccines, and oncolytic virotherapy to activate the immune system against cancer tumors.

Australia
Address Level 12/4-6 Bligh St, Sydney, NSW, 2000, Australia
Business Type Clinical Stage Immuno-Oncology Company
Primary Focus Cancer Immunotherapies, CAR T-Cell Therapy, Oncolytic Virotherapy
Established 1986
Annual Revenue $6.478M 2025

About This Company

Imugene is a clinical-stage immuno-oncology company developing a range of new treatments designed to activate the immune system of cancer patients to identify and eradicate tumors. Our unique platform technologies aim to harness the body’s immune system against tumors, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibodies and other immunotherapies.

We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies, many of which have been approved for sale and marketing in global markets. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR-T drug, Azer-cel (azercabtagene zapreleucel), which targets CD19 to treat blood cancers. Additionally, our pipeline features multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating various cancers.

Location